Thiogenesis Therapeutics Corp. (TTI : TSX-V)
Common Stock
$0.64
CAD
+0.01 (1.59%)
Last updated: 2026-11-06
Follow TTI
TTI
Thiogenesis Therapeutics Corp.
WealthAwesomePerformance
1 Day
+1.59%
1 Week
+3.23%
1 Month
+30.61%
YTD
-1.54%
Key Statistics
Market Cap
$44.79M
52W High
$0.74
52W Low
$0.44
P/E Ratio
-
50 Day MA
$0.54
200 Day MA
$0.55
Beta
0.61
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/6/2026 | $0.61 | $0.64 | $0.61 | $0.64 | $0.64 | 6,100 |
| 11/5/2026 | $0.60 | $0.63 | $0.60 | $0.63 | $0.63 | 10,000 |
| 11/4/2026 | $0.64 | $0.64 | $0.63 | $0.63 | $0.63 | 12,000 |
| 11/2/2026 | $0.65 | $0.65 | $0.63 | $0.63 | $0.63 | 19,156 |
| 10/30/2026 | $0.63 | $0.63 | $0.62 | $0.62 | $0.62 | 19,000 |
| 10/29/2026 | $0.63 | $0.64 | $0.63 | $0.64 | $0.64 | 31,343 |
| 10/28/2026 | $0.63 | $0.63 | $0.63 | $0.63 | $0.63 | 500 |
| 10/27/2026 | $0.63 | $0.63 | $0.62 | $0.62 | $0.62 | 51,500 |
| 10/26/2026 | $0.62 | $0.64 | $0.62 | $0.64 | $0.64 | 130,566 |
| 10/23/2026 | $0.60 | $0.62 | $0.60 | $0.62 | $0.62 | 28,000 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TTI's historical volatility
30-Day Vol
85.5%
Annualized
90-Day Vol
64.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.68 | C$0.51 – C$0.91 |
| 60 trading days | C$0.72 | C$0.48 – C$1.09 |
| 90 trading days | C$0.77 | C$0.46 – C$1.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -181.53%
- EPS (Diluted)
- -0.12
- Book Value
- 0.10
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About TTI
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SPSA-P | SP Strategic Acquisition Corp. | $0.04 | +133.33% |
| BIGT | Big Tree Carbon Inc. | $0.01 | +100.00% |
| DEAL | Playgon Games Inc | $0.01 | +100.00% |
| DELX | DelphX Capital Markets Inc | $0.01 | +100.00% |
| ENEV | Enerev5 Metals Inc | $0.01 | +100.00% |
| MTLO | Martello Technologies Group Inc | $0.01 | +100.00% |
| RUN-H | Running Fox Resource Corp | $0.01 | +100.00% |
| TTGI | Turnium Technology Group Inc. | $0.03 | +66.67% |
TTI.V news timeline
4 articles covering TTI.V, most recent first
Latest